Enhertu Approved to Treat HER2-Positive Breast Cancer Following 2 or More Prior Anti-HER2 Therapies
Results showed a confirmed ORR of 60.3% including a 4.3% complete response rate and 56.0% partial response rate, with a median DOR of 14.8 months.
Results showed a confirmed ORR of 60.3% including a 4.3% complete response rate and 56.0% partial response rate, with a median DOR of 14.8 months.
SFA001 blocked the progression of hepatitis B to HCC in transgenic HBX animal models